# LIV-2008/2008b

Source: https://onco.cc/drugs/liv-2008-2008b/  
OnCo record `liv-2008-2008b` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LIV-2008/2008b is an experimental humanized monoclonal antibody from Chiome Bioscience, in preclinical development for triple-negative breast cancer, lung cancer and colorectal cancer.

## Summary

LIV-2008/2008b (LIV-2008, LIV-2008b) is a humanized monoclonal antibody from Chiome Bioscience. A humanized anti-TROP-2 (TROP2) antibody generated by hybridoma technology. Its furthest stage is preclinical development, for triple-negative breast cancer, lung cancer and colorectal cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Listed as 'Licensing opportunity'. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Also known as: LIV-2008; LIV-2008b
- Tags: pipeline
- Code: LIV-2008/2008b
- Modality: Humanized monoclonal antibody
- Mechanism: A humanized anti-TROP-2 (TROP2) antibody generated by hybridoma technology.

## Sources

- Chiome Bioscience: chiome.co.jp: https://www.chiome.co.jp/en/pipeline/

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- companies: [Chiome Bioscience](https://onco.cc/companies/chiome-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/liv-2008-2008b.json